Table 3 HIF-1α polymorphisms in various cancers
|
Type of cancer (Reference No.) | Case | Frequency (%) | Prognosis | ||
|---|---|---|---|---|---|
| C1772T | G1790A | C1772T | G1790A | ||
| OCCC (present study) | 89 | 23.6 | 3.3 | No association | No association |
| Colorectal cancer (21) | 336 | 20.6 | 2.7 | No association | No association |
| Colorectal cancer (22) | 445 | 7.9 | 7.0 | No association | No association |
| NSCLC (13) | 741 | 73.5 | 72.5 | CC has longer survival than CT and TT | No association |
| NSCLC (14) | 285 | 46.3 | 47.4 | TT has shorter survival than CC and CT | AA has shorter survival than GG and GA |
| Breast cancer (15) | 90 | 10.0 | 3.3 |
C1772T polymorphism is associated with HIF-1α overexpression, found in patients with lymph node metastasis | No association |
| Breast cancer (16) | 410 | 28.2 | 19.1 | T allele increases risk for lymph nodes metastasis | No association |
| Prostate cancer (18) | 754 | 21.9 | NA | T allele increases risk for metastasis and resistance to ADT | NA |
| RCC (23) | 160 | 90.0 | 55.5 | TT is earlier stage than the CC and CT | No association |
| RCC (24) | 620 | 7.7 | 7.3 | No association | No association |
| HNSCC (17) | 52 | 50.0 | 71.2 | T allele is more frequently found in patients with metastasis | GA and GG have shorter survival than AA |
| OSCC (25) | 305 | 7.5 | 7.9 | No association | No association |
| OSCC (26) | 74 | 18.6 | 37.5 | No association | A allele has shorter survival |
| Thymic malignancy (27) | 57 | 14.9 | 0 | No association | NA |
| Bladder cancer (19) | 219 | 10.0 | 6.8 | C1772T and/or G1790A polymorphic variants have shorter survival | |
| Cervical cancer (28) | 162 | 14.2 | 6.8 | No association | No association |
| Cervical cancer (29) | 199 | 11.1 | 6.0 | No association | No association |
| Glioma (20) | 387 | 70.5 | 75.2 | CC has longer survival than CT and TT | No association |